Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment

Abstract

OBJECTIVEDiabetic patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73 m2) are at particular cardiovascular risk. Fenofibrate’s safety in these patients is an issue because it may elevate plasma creatinine. Furthermore, guidelines regarding fenofibrate dosing in renal impairment vary internationally. We investigated fenofibrate’s effects on cardiovascular and end-stage renal disease (ESRD) events, according to eGFR, in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.RESEARCH DESIGN AND METHODSType 2 diabetic patients (aged 50–75 years) with eGFR ≥30 mL/min/1.73 m2 were randomly allocated to a fixed dose of fenofibrate (200 mg daily) (n = 4,895) or placebo (n = 4,900) for 5 years. Baseline renal function (Modification of Diet in Renal Disease equation) was grouped by eGFR (30–59, 60–89, and ≥90 mL/min/1.73 m2). The prespecified outcome was total cardiovascular events (composite of cardiovascular death, myocardial infarction, stroke, and coronary/carotid revascularization). Serious adverse events and instances of ESRD (plasma creatinine >400 μmol/L, dialysis, renal transplant, or renal death) were recorded. Analysis was by intention to treat.RESULTSOverall, fenofibrate reduced total cardiovascular events, compared with placebo (hazard ratio 0.89 [95% CI 0.80–0.99]; P = 0.035). This benefit was not statistically different across eGFR groupings (P = 0.2 for interaction) (eGFR 30–59 mL/min/1.73 m2: 0.68 [0.47–0.97], P = 0.035; eGFR ≥90 mL/min/1.73 m2: 0.85 [0.70–1.02], P = 0.08). ESRD rates were similar between treatment arms, without adverse safety signals of fenofibrate use in renal impairment.CONCLUSIONSPatients with type 2 diabetes and moderate renal impairment benefit from long-term fenofibrate, without excess drug-related safety concerns compared with those with no or mild renal impairment. Fenofibrate treatment should not be contraindicated in moderate renal impairment, suggesting that current guidelines may be too restrictive.

Residual Microvascular Risk in Type 2 Diabetes in 2014: Is it Time for a Re-Think? A Perspective from the Residual Risk Reduction Initiative (R3i)

“…While patients in the placebo group of this study with moderate renal impairment had the highest cardiovascular event rates, fenofibrate treatment was associated with a relative reduction in cardiovascular risk of 32% versus 15% in patients with normal renal function [53]. Admittedly, this analysis was based on a limited sample (~5% of the total study population), and the use of the Modification of Diet in Renal Disease formula in FIELD may have underestimated eGFR.…”

Dyslipidemia aterogenna w codziennej praktyce — interdyscyplinarny konsensus polskich ekspertów

“…W badaniu wykazano również możliwość korzystnego efektu terapii skojarzonej w postaci redukcji o 30% incydentów sercowo-naczyniowych u osób z równoczesnym wysokim stężeniem TG (≥ 204 mg/dl) i niskim stężeniem HDL-C (≤ 34 mg/dl). W żadnym z wymienionych badań przejściowy wzrost stężenia kreatyniny w surowicy krwi nie skutkował działaniami niepożądanymi w zakresie poważnych zdarzeń nerkowych, co sugeruje możliwe korzyści przy długotrwałej terapii [38][39][40][41][42].…”

Lipid-lowering agents in chronic kidney disease: do fibrates have a role?

“…The investigators concluded that fenofibrate should be considered as an additional therapeutic option, along with conventional risk-factor management, to further reduce CVD events and m ortality and provide renoprotection to patients with diabetes, as well as to those with moderate renal impairment. 8 9 the addition of fenofibrate (160 mg daily) to simvastatin treatment (10-40 mg daily) was assessed in 5,518 participants with diabetes. No significant difference was found in the primary outcome of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death.…”